Beta

Gain therapeutics, inc.GANX.US Overview

US StockHealthcare
(No presentation for GANX)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

GANX AI Insights

GANX Overall Performance

GANX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

GANX Recent Performance

-5.13%

Gain therapeutics, inc.

-1.10%

Avg of Sector

-0.49%

S&P500

GANX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check GANX's Trend

GANX Key Information

GANX Valuation Metrics

GANX Profile

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.

Price of GANX

GANX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

GANX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.48
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
255.50
PB Ratio
4.51
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.48
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
255.50
PB Ratio
4.51
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is GANX's latest earnings report released?

    The most recent financial report for Gain therapeutics, inc. (GANX) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating GANX's short-term business performance and financial health. For the latest updates on GANX's earnings releases, visit this page regularly.

  • How much debt does GANX have?

    As of the end of the reporting period, Gain therapeutics, inc. (GANX) had total debt of 732.07K, with a debt ratio of 0.03. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does GANX have?

    At the end of the period, Gain therapeutics, inc. (GANX) held Total Cash and Cash Equivalents of 20.84M, accounting for 0.91 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • What is the FCF of GANX?

    Gain therapeutics, inc. (GANX)'s Free Cash Flow (FCF) for the period is -4.62M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 33.65% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of GANX?

    The latest valuation data shows Gain therapeutics, inc. (GANX) has a Price-To-Earnings (PE) ratio of -3.96 and a Price/Earnings-To-Growth (PEG) ratio of 0.22. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.